VERO Venus Concept

Venus Concept Announces the Launch of its latest generation of ARTAS iX, the World’s Most Advanced Robotic Hair Restoration System

Venus Concept Announces the Launch of its latest generation of ARTAS iX, the World’s Most Advanced Robotic Hair Restoration System

TORONTO, March 20, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the launch of its latest generation of ARTAS iX, which is now broadly available to physicians specializing in hair transplantation worldwide.

Its latest generation of ARTAS iX sets a new standard for hair transplantation by leveraging cutting-edge robotics, machine vision, artificial intelligence, and machine learning technologies. This advanced system offers a new level of speed to the implantation process, now allowing the implantation of up to 1000 grafts per hour while also improving the speed of harvesting, resulting in a procedure that is up to 25% faster. Additional improvements include the new vision system, which improves patient tracking and follicle centering, resulting in better graft quality and enhanced precision. In addition to these significant hardware advancements, our enhanced software enables an improved, intuitive user experience with a refreshed user interface and a new training mode to enable smoother training of practitioners and run real-time demos during consultations.

"We continue to focus on integrating the advancements of robotics and artificial intelligence into the area of minimally-invasive aesthetic and hair restoration procedures,” said Dr. Hemanth Varghese, President and Chief Innovation & Business Officer of Venus Concept. "The market for hair restoration continues to grow, and with it, the demand for better solutions to optimize procedure workflow and clinical outcomes. Our enhanced ARTAS iX system marks another major achievement for our Robotics Center of Excellence in its continuous innovation towards revolutionizing hair transplantation. The system enables physicians to generate unparalleled results offering state-of-the-art precision and accuracy levels as well as speed, helping to address concerns related to the labor-intensive aspects of hair restoration procedures such as clinical fatigue and procedure time. Hair restoration is an important segment for Venus Concept and will continue to be a driver of growth into the future. "

"I have found that the new upgrades to the ARTAS iX system significantly improve the process of transplantation, handling of harvested grafts, site-making and implantation, all of which contribute to reducing training time and increasing staff bandwidth," commented Dr. Maxim Chumak, an ARTAS iX system user and a diplomate of the American Board of Hair Restoration Surgery. "Most of the devices currently on the market require manual operation for harvesting and for implanters to be loaded individually, which can be time-consuming and can potentially damage grafts. This is the first system that requires minimal handling of the grafts, effectively addressing this issue. "

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 15 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.



Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept
Mike Piccinino, CFA
 
EN
20/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Venus Concept

 PRESS RELEASE

Venus Concept Announces Intention to Voluntary Delist from Nasdaq and ...

Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and deregister its common stock with the Securities and Exchange Commission (the “SEC”). The Company is in compliance with applicable Nasdaq listing requirements, but the Company’s Board of Directors has concluded the resources required to continue its reporting obligations with the SEC are great...

 PRESS RELEASE

Venus Concept Announces Third Quarter 2025 Financial Results

Venus Concept Announces Third Quarter 2025 Financial Results TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device (“EBD”) revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% qua...

 PRESS RELEASE

Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Mu...

Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments Venus NOVA is the first product clearance from the Company’s new R&D strategy TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus NOVA™, the Company’s next-generation multi-application platform designed to redefine non-invasive treatm...

 PRESS RELEASE

Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transac...

Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction Reduction of outstanding debt by Madryn Asset Management continues to improve the Company’s financial position TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 545,335 shares of its Series Y preferred stock...

 PRESS RELEASE

Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial R...

Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025 TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to par...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch